Cargando…
"Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection
Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756105/ https://www.ncbi.nlm.nih.gov/pubmed/36540317 http://dx.doi.org/10.7759/cureus.32548 |
_version_ | 1784851561993732096 |
---|---|
author | Castillo-Aleman, Yandy M Villegas-Valverde, Carlos A Ventura-Carmenate, Yendry Suarez-Formigo, Gisela M Bencomo-Hernandez, Antonio A |
author_facet | Castillo-Aleman, Yandy M Villegas-Valverde, Carlos A Ventura-Carmenate, Yendry Suarez-Formigo, Gisela M Bencomo-Hernandez, Antonio A |
author_sort | Castillo-Aleman, Yandy M |
collection | PubMed |
description | Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article aims to provide an immunological explanation for the delayed side effects of a SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of a 39-year-old male healthcare worker who complained about pruritus and discomfort around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 17, and 13 months earlier. Those symptoms resembled the side effects previously experienced with one of the booster doses, and a sole erythematous papule was also documented. The patient was diagnosed with COVID-19 one or two days after noticing these local signs and symptoms, and high serum titers of immunoglobulin M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS might be a plausible phenomenon to consider in individuals immunized with inactivated vaccines and exposed secondarily to a wild virus with antigenic variations. |
format | Online Article Text |
id | pubmed-9756105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Cureus |
record_format | MEDLINE/PubMed |
spelling | pubmed-97561052022-12-19 "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection Castillo-Aleman, Yandy M Villegas-Valverde, Carlos A Ventura-Carmenate, Yendry Suarez-Formigo, Gisela M Bencomo-Hernandez, Antonio A Cureus Internal Medicine Although the "original antigenic sin" (OAS) effects have been predicted against new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), only a few pieces of evidence are available regarding its impact on the safety and effectiveness of coronavirus disease 2019 (COVID-19) vaccines. This article aims to provide an immunological explanation for the delayed side effects of a SARS-CoV-2 vaccine during an episode of natural infection. We reported a case of a 39-year-old male healthcare worker who complained about pruritus and discomfort around the injection site of an inactivated SARS-CoV-2 vaccine administrated 18, 17, and 13 months earlier. Those symptoms resembled the side effects previously experienced with one of the booster doses, and a sole erythematous papule was also documented. The patient was diagnosed with COVID-19 one or two days after noticing these local signs and symptoms, and high serum titers of immunoglobulin M (IgM) and immunoglobulin E (IgE) were found five weeks after the onset, along with SARS-CoV-2-specific immunoglobulin G (IgG) antibodies. Therefore, the OAS might be a plausible phenomenon to consider in individuals immunized with inactivated vaccines and exposed secondarily to a wild virus with antigenic variations. Cureus 2022-12-15 /pmc/articles/PMC9756105/ /pubmed/36540317 http://dx.doi.org/10.7759/cureus.32548 Text en Copyright © 2022, Castillo-Aleman et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Internal Medicine Castillo-Aleman, Yandy M Villegas-Valverde, Carlos A Ventura-Carmenate, Yendry Suarez-Formigo, Gisela M Bencomo-Hernandez, Antonio A "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection |
title | "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection |
title_full | "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection |
title_fullStr | "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection |
title_full_unstemmed | "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection |
title_short | "Original Antigenic Sin" in SARS-CoV-2 Vaccination Followed by Infection |
title_sort | "original antigenic sin" in sars-cov-2 vaccination followed by infection |
topic | Internal Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9756105/ https://www.ncbi.nlm.nih.gov/pubmed/36540317 http://dx.doi.org/10.7759/cureus.32548 |
work_keys_str_mv | AT castilloalemanyandym originalantigenicsininsarscov2vaccinationfollowedbyinfection AT villegasvalverdecarlosa originalantigenicsininsarscov2vaccinationfollowedbyinfection AT venturacarmenateyendry originalantigenicsininsarscov2vaccinationfollowedbyinfection AT suarezformigogiselam originalantigenicsininsarscov2vaccinationfollowedbyinfection AT bencomohernandezantonioa originalantigenicsininsarscov2vaccinationfollowedbyinfection |